Bath & Body Works (NYSE:BBWI – Get Free Report) had its price target lowered by equities researchers at BMO Capital Markets from $24.00 to $20.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets‘s price objective indicates a potential upside of 7.12% from the stock’s current price.
A number of other research firms also recently issued reports on BBWI. Citigroup raised Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Tuesday, August 18th. Robert W. Baird lowered their target price on Bath & Body Works from $23.00 to $22.00 and set a “neutral” rating for the company in a research report on Friday. Argus reiterated a “hold” rating on shares of Bath & Body Works in a research report on Wednesday, September 16th. Morgan Stanley cut their target price on shares of Bath & Body Works from $22.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Bath & Body Works from $22.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.00.
Read Our Latest Stock Analysis on BBWI
Bath & Body Works Trading Down 1.3%
Bath & Body Works (NYSE:BBWI – Get Free Report) last issued its earnings results on Thursday, November 19th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.14. Bath & Body Works had a negative return on equity of 57.47% and a net margin of 10.32%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter last year, the company earned $0.37 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. Bath & Body Works has set its Q4 2026 guidance at 1.410-1.610 EPS and its FY 2026 guidance at 2.600-2.800 EPS. On average, research analysts predict that Bath & Body Works will post 2.77 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bath & Body Works
Several large investors have recently added to or reduced their stakes in the stock. Elevation Wealth Partners LLC increased its stake in Bath & Body Works by 5,278.8% during the second quarter. Elevation Wealth Partners LLC now owns 1,775 shares of the company’s stock worth $41,000 after acquiring an additional 1,742 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of Bath & Body Works by 35.5% in the 1st quarter. Parallel Advisors LLC now owns 2,570 shares of the company’s stock valued at $48,000 after purchasing an additional 673 shares during the last quarter. United Southern Bank Trust Department bought a new stake in shares of Bath & Body Works in the 3rd quarter valued at approximately $58,000. Meeder Asset Management Inc. bought a new stake in shares of Bath & Body Works in the 2nd quarter valued at approximately $66,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Bath & Body Works in the 2nd quarter worth approximately $71,000. 95.14% of the stock is owned by institutional investors.
More Bath & Body Works News
Investors following BBWI have been watching these news items:
- Positive Sentiment: The company raised its full-year sales outlook and announced a new $500 million share-repurchase program. It maintained adjusted FY2026 EPS guidance of $2.60–$2.80. Bath & Body Works Q3 results and outlook
- Negative Sentiment: Q4 EPS guidance of $1.41–$1.61 came in below the $1.72 analyst consensus, with revenue guidance also below expectations at the midpoint. Reports of softer expected holiday sales add to concerns about near-term demand. Bath & Body Works trims FY26 EPS outlook
- Negative Sentiment: Several firms lowered their BBWI price targets after the results, including UBS ($22 to $19), BMO ($24 to $20), and JPMorgan ($24 to $23). Most maintained neutral or equivalent ratings, signaling caution despite targets generally remaining above the recent share price. UBS Group rating and price target
About Bath & Body Works
Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.
Further Reading
- Five stocks we like better than Bath & Body Works
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.
